Michael Fradley, Cardiologist/electrophysiologist, Medical Director of the Penn Cardio-Oncology Program, and Associate Professor of Clinical Medicine at the University of Pennsylvania shared a post on LinkedIn:
”Honored to present real world data evaluating cardiovascular outcomes and health care utilization in CLL patients treats with BTK inhibitors.
Bottom line: Afib is common and leads to more adverse outcomes and stress on the health care system.
We need to improve early risk factor modification and guideline directed treatment of AFib in these patients.”
Other Articles Featuring Michael Fradley On OncoDaily.